Outcomes of treatment choices in poor prognosis prostate cancer: not against all odds

Ann Oncol. 2021 Jul;32(7):831-832. doi: 10.1016/j.annonc.2021.04.016. Epub 2021 Apr 27.

Authors

D G J Robbrecht¹, S A J Buck¹, R de Wit²

Affiliations

¹ Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
² Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands. Electronic address: r.dewit@erasmusmc.nl.

PMID: 33930524
DOI: 10.1016/j.annonc.2021.04.016

No abstract available

Publication types

Editorial
Comment

MeSH terms

Androstenes
Benzamides
Humans
Male
Nitriles
Phenylthiohydantoin
Prognosis
Prostatic Neoplasms* / diagnosis
Prostatic Neoplasms* / drug therapy
Prostatic Neoplasms, Castration-Resistant*
Taxoids
Treatment Outcome

Substances

Androstenes
Benzamides
Nitriles
Taxoids
Phenylthiohydantoin
cabazitaxel
enzalutamide
abiraterone